Compare Strategy Inc. (MSTR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Summit Therapeutics Inc — how do they compare? Strategy Inc. trades at $102.38 (market cap $35.47B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Strategy Inc. is far larger — about 3.4× Summit Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| MSTR | SMMT | |
|---|---|---|
Market Cap | $35.47B | $10.48B |
Sector | Technology | Health |
52-Week High | $426.40 | $29.32 |
52-Week Low | $82.31 | $13.05 |
Enterprise Value | $50.50B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $101.95, up 7.49% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of -$38.25, missing expectations, while Q3 2025 showed a positive surprise. Revenue remains stable near $477M, but net income margin is deeply negative at -806.35%. Recent news highlights institutional stake adjustments and strategic Bitcoin-related capital moves, influencing investor sentiment.
Outlook is mixed: analyst consensus targets $237.63 with 62% buy ratings, suggesting significant upside, but high valuation multiples and persistent losses pose risks. Key opportunities include potential Bitcoin adoption benefits, while risks involve earnings volatility and debt levels. Investors should weigh strong analyst optimism against fundamental challenges.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
